Alaa Elwan

1.1k total citations
37 papers, 992 citations indexed

About

Alaa Elwan is a scholar working on Organic Chemistry, Molecular Biology and Toxicology. According to data from OpenAlex, Alaa Elwan has authored 37 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Organic Chemistry, 22 papers in Molecular Biology and 13 papers in Toxicology. Recurrent topics in Alaa Elwan's work include Synthesis and biological activity (20 papers), Angiogenesis and VEGF in Cancer (15 papers) and Bioactive Compounds and Antitumor Agents (13 papers). Alaa Elwan is often cited by papers focused on Synthesis and biological activity (20 papers), Angiogenesis and VEGF in Cancer (15 papers) and Bioactive Compounds and Antitumor Agents (13 papers). Alaa Elwan collaborates with scholars based in Egypt, Saudi Arabia and Indonesia. Alaa Elwan's co-authors include Ibrahim H. Eissa, Hazem Elkady, Eslam B. Elkaeed, Hazem A. Mahdy, Mohammed S. Taghour, Abdel‐Ghany A. El‐Helby, Khaled El‐Adl, Helmy Sakr, Mohammed A. Dahab and Nawaf A. Alsaif and has published in prestigious journals such as International Journal of Molecular Sciences, Molecules and RSC Advances.

In The Last Decade

Alaa Elwan

34 papers receiving 985 citations

Peers

Countries citing papers authored by Alaa Elwan

Since Specialization

Citations

This map shows the geographic impact of Alaa Elwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alaa Elwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alaa Elwan more than expected).

Fields of papers citing papers by Alaa Elwan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alaa Elwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alaa Elwan. The network helps show where Alaa Elwan may publish in the future.

Co-authorship network of co-authors of Alaa Elwan

This figure shows the co-authorship network connecting the top 25 collaborators of Alaa Elwan. A scholar is included among the top collaborators of Alaa Elwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alaa Elwan. Alaa Elwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of oxadiazole- N -phenylacetamide conjugates as VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative assessment, molecular docking, and dynamics studies 2025 ·Future Medicinal Chemistry ·(unknown), Rezk R. Ayyad, İ. Çelik, Helmy Sakr, Alaa Elwan	0
2	Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study 2025 ·RSC Advances ·(unknown), Arafa Musa, (unknown), (unknown), (unknown), Mohamed Ayman El‐Zahabi, Alaa Elwan	0
3	Targeting VEGFR-2 in breast cancer: synthesis and in silico and in vitro characterization of quinoxaline-based inhibitors 2025 ·RSC Advances ·Ibrahim H. Eissa, Alaa Elwan, (unknown), Dalal Z. Husein, (unknown), Aisha A. Alsfouk, Eslam B. Elkaeed, Hazem Elkady, Ahmed M. Metwaly	6
4	2,3-Dihydro-1,3,4-thiadiazoles as dual B-Raf / VEGFR-2 inhibitors: Design, synthesis, and anti-breast cancer assessment 2025 ·Journal of Molecular Structure ·Walid E. Elgammal, Hazem Elkady, Hazem A. Mahdy, Alaa Elwan, Dalal Z. Husein, (unknown), Bshra A. Alsfouk, Eslam B. Elkaeed, Ibrahim H. Eissa, Ahmed M. Metwaly	0
5	New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies 2024 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Hazem Elkady, Hazem A. Mahdy, Mohammed S. Taghour, Mohammed A. Dahab, Alaa Elwan, Mohamed Hagras, (unknown), Ibrahim M. Ibrahim, Dalal Z. Husein, Eslam B. Elkaeed, Aisha A. Alsfouk, Ahmed M. Metwaly, Ibrahim H. Eissa	13
6	Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers 2024 ·Future Medicinal Chemistry ·Reda G. Yousef, Ibrahim H. Eissa, Hazem Elkady, Taha Mehany, (unknown), Mohamed M. Radwan, Mahmoud A. ElSohly, (unknown), Alaa Elwan, Mohamed Ayman El‐Zahabi	4
7	New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies 2023 ·Computational Biology and Chemistry ·Hazem Elkady, (unknown), (unknown), Mohammed S. Taghour, Mohammed A. Dahab, Hazem A. Mahdy, Alaa Elwan, Hanan Al-Ghulikah, Eslam B. Elkaeed, Ibrahim M. Ibrahim, Dalal Z. Husein, Ahmed M. Metwaly, Ibrahim H. Eissa	16
8	Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors 2023 ·RSC Advances ·Hazem Elkady, (unknown), Alaa Elwan, Mohammed S. Taghour, Hazem A. Mahdy, Mohammed A. Dahab, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Dalal Z. Husein, E. S. E. Hafez, Amira M.G. Darwish, Ahmed M. Metwaly, Ibrahim H. Eissa	16
9	New Theobromine Derivatives Inhibiting VEGFR-2: Design, Synthesis, Antiproliferative, Docking and Molecular Dynamics Simulations 2023 ·Future Medicinal Chemistry ·Hazem A. Mahdy, Hazem Elkady, Mohammed S. Taghour, Alaa Elwan, Mohammed A. Dahab, Mohamed A. Elkady, Elsayed G.E. Elsakka, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Ibrahim H. Eissa, Ahmed M. Metwaly	24
10	VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS 2023 ·Al-Azhar Journal of Pharmaceutical Sciences ·Helmy Sakr, (unknown), Rezk R. Ayyad, Alaa Elwan	2
11	Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation 2022 ·Molecules ·Alaa Elwan, Abdallah E. Abdallah, Hazem A. Mahdy, Mohammed A. Dahab, Mohammed S. Taghour, Eslam B. Elkaeed, Ahmed B. M. Mehany, (unknown), (unknown), Aisha A. Alsfouk, Hazem Elkady, Ibrahim H. Eissa	51
12	Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Ibrahim H. Eissa, Radwan El‐Haggar, Mohammed A. Dahab, Marwa F. Ahmed, Hazem A. Mahdy, Reem I. Alsantali, Alaa Elwan, Nicolas Masurier, Samar S. Fatahala	17
13	A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease 2022 ·International Journal of Molecular Sciences ·Eslam B. Elkaeed, Ibrahim H. Eissa, Hazem Elkady, (unknown), (unknown), Aisha A. Alsfouk, Alaa Elwan, Ahmed M. Metwaly	44
14	Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Alaa Elwan, Helmy Sakr, Abdel‐Ghany A. El‐Helby, Ahmed El-morsy, Mohamed A. Abdelgawad, Mohammed M. Ghoneim, (unknown), Khaled El‐Adl	11
15	Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2 2022 ·Molecules ·Reda G. Yousef, Wagdy M. Eldehna, Alaa Elwan, (unknown), Ahmed B. M. Mehany, (unknown), Bshra A. Alsfouk, Eslam B. Elkaeed, Ahmed M. Metwaly, Ibrahim H. Eissa	17
16	Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Mohammed S. Taghour, Hazem A. Mahdy, (unknown), (unknown), (unknown), Alaa Elwan, Mohammed A. Dahab, Eslam B. Elkaeed, Aisha A. Alsfouk, Mohamed M. Khalifa, Ibrahim H. Eissa, Hazem Elkady	43
17	Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Nawaf A. Alsaif, Mohammed S. Taghour, Mohammed M. Alanazi, Ahmad J. Obaidullah, Abdulrahman A. Almehizia, (unknown), (unknown), Alaa Elwan, Hazem Elkady	57
18	Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Mohammed M. Alanazi, Alaa Elwan, Nawaf A. Alsaif, Ahmad J. Obaidullah, Hamad M. Alkahtani, Abdulrahman A. Almehizia, (unknown), Mohammed S. Taghour, Ibrahim H. Eissa	45
19	Targeting VEGFR‐2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies 2021 ·Archiv der Pharmazie ·Nawaf A. Alsaif, Hazem A. Mahdy, Mohammed M. Alanazi, Ahmad J. Obaidullah, Hamad M. Alkahtani, (unknown), (unknown), Alaa Elwan, Mohammed S. Taghour	21
20	New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Hazem Elkady, Alaa Elwan, Hesham A. El‐Mahdy, Ahmed S. Doghish, Ahmed Ismail, Mohammed S. Taghour, Eslam B. Elkaeed, Ibrahim H. Eissa, Mohammed A. Dahab, Hazem A. Mahdy, Mohamed M. Khalifa	112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact